Your browser doesn't support javascript.
loading
Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.
Boutard, Nicolas; Bialas, Arkadiusz; Sabiniarz, Aleksandra; Guzik, Pawel; Banaszak, Katarzyna; Biela, Artur; Bien, Marcin; Buda, Anna; Bugaj, Barbara; Cieluch, Ewelina; Cierpich, Anna; Dudek, Lukasz; Eggenweiler, Hans-Michael; Fogt, Joanna; Gaik, Monika; Gondela, Andrzej; Jakubiec, Krzysztof; Jurzak, Mirek; Kitlinska, Agata; Kowalczyk, Piotr; Kujawa, Maciej; Kwiecinska, Katarzyna; Les, Marcin; Lindemann, Ralph; Maciuszek, Monika; Mikulski, Maciej; Niedziejko, Paulina; Obara, Alicja; Pawlik, Henryk; Rzymski, Tomasz; Sieprawska-Lupa, Magdalena; Sowinska, Marta; Szeremeta-Spisak, Joanna; Stachowicz, Agata; Tomczyk, Mateusz M; Wiklik, Katarzyna; Wloszczak, Lukasz; Ziemianska, Sylwia; Zarebski, Adrian; Brzózka, Krzysztof; Nowak, Mateusz; Fabritius, Charles-Henry.
Afiliação
  • Boutard N; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Bialas A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Sabiniarz A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Guzik P; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Banaszak K; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Biela A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Bien M; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Buda A; Current address: Almac Group, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, UK.
  • Bugaj B; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Cieluch E; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Cierpich A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Dudek L; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Eggenweiler HM; Current address: Grupa Azoty S.A., Kwiatkowskiego 8, 33-100, Tarnów, Poland.
  • Fogt J; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Gaik M; Medicinal Chemistry, Merck Biopharma, Merck KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
  • Gondela A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Jakubiec K; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Jurzak M; Current address: Max Planck Research Group at the Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
  • Kitlinska A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Kowalczyk P; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Kujawa M; Discovery Pharmacology, Merck Biopharma, Merck KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
  • Kwiecinska K; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Les M; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Lindemann R; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Maciuszek M; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Mikulski M; Current address: Captor Therapeutics, Dunska 11, 54-427, Wroclaw, Poland.
  • Niedziejko P; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Obara A; Translational Innovation Platform Oncology, Merck Biopharma, Merck KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
  • Pawlik H; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Rzymski T; Current address: LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK.
  • Sieprawska-Lupa M; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Sowinska M; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Szeremeta-Spisak J; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Stachowicz A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Tomczyk MM; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Wiklik K; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Wloszczak L; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Ziemianska S; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Zarebski A; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Brzózka K; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Nowak M; Current address: Katedra Chemii Organicznej, Bioorganicznej I Biotechnologii, Ul. B. Krzywoustego 4, P., 18/N1, 44-100, Gliwice, Poland.
  • Fabritius CH; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
ChemMedChem ; 14(1): 169-181, 2019 01 08.
Article em En | MEDLINE | ID: mdl-30378281
ABSTRACT
Energy and biomass production in cancer cells are largely supported by aerobic glycolysis in what is called the Warburg effect. The process is regulated by key enzymes, among which phosphofructokinase PFK-2 plays a significant role by producing fructose-2,6-biphosphate; the most potent activator of the glycolysis rate-limiting step performed by phosphofructokinase PFK-1. Herein, the synthesis, biological evaluation and structure-activity relationship of novel inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which is the ubiquitous and hypoxia-induced isoform of PFK-2, are reported. X-ray crystallography and docking were instrumental in the design and optimisation of a series of N-aryl 6-aminoquinoxalines. The most potent representative, N-(4-methanesulfonylpyridin-3-yl)-8-(3-methyl-1-benzothiophen-5-yl)quinoxalin-6-amine, displayed an IC50 of 14 nm for the target and an IC50 of 0.49 µm for fructose-2,6-biphosphate production in human colon carcinoma HCT116 cells. This work provides a new entry in the field of PFKFB3 inhibitors with potential for development in oncology.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinoxalinas / Fosfofrutoquinase-2 / Inibidores Enzimáticos / Descoberta de Drogas Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinoxalinas / Fosfofrutoquinase-2 / Inibidores Enzimáticos / Descoberta de Drogas Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article